Edwards Lifesciences Corporation $EW Shares Sold by Peapack Gladstone Financial Corp

Peapack Gladstone Financial Corp decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 3.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 261,416 shares of the medical research company’s stock after selling 8,244 shares during the period. Peapack Gladstone Financial Corp’s holdings in Edwards Lifesciences were worth $22,286,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after buying an additional 365,581 shares in the last quarter. Wellington Management Group LLP increased its holdings in Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock valued at $1,617,959,000 after buying an additional 977,933 shares in the last quarter. Norges Bank purchased a new position in Edwards Lifesciences in the fourth quarter valued at $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. Finally, Holocene Advisors LP increased its holdings in Edwards Lifesciences by 0.9% in the third quarter. Holocene Advisors LP now owns 4,746,694 shares of the medical research company’s stock valued at $369,150,000 after buying an additional 42,717 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 95,057 shares of company stock worth $7,874,217 in the last 90 days. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on EW. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Robert W. Baird lifted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Stock Down 0.1%

EW stock opened at $86.41 on Monday. The stock has a market capitalization of $49.76 billion, a P/E ratio of 45.96, a P/E/G ratio of 2.17 and a beta of 0.87. The firm has a 50-day simple moving average of $81.73 and a 200-day simple moving average of $83.00. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $88.28.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the prior year, the company earned $0.64 EPS. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.